comparemela.com

Latest Breaking News On - Mantle cell lymphoma - Page 5 : comparemela.com

Bristol-Myers Squibb Company (NYSE:BMY) Q4 2023 Earnings Call Transcript

Bristol-Myers Squibb Company (NYSE:BMY) Q4 2023 Earnings Call Transcript February 2, 2024 Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers Squibb Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-only […]

Japan
Chronic-lymphocytic-leukemia
Mantle-cell-lymphoma
Massive-vote
Approval-from-wall-street-analysts
Bristol-myers-squibb-company
Fourth-quarter
David-elkins
Jim-power
Forward-looking-statement
Chris-boerner

Dr Danilov on Using MRD Status to Predict Outcomes in Hematologic Malignancies

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Alexey-danilov
Toni-stephenson-lymphoma-center
Department-of-hematology-hematopoietic-cell-transplantation
Division-of-leukemia
Hematopoietic-cell-transplantation
Onclive-tv
Hematologic-oncology
Mantle-cell-lymphoma

Covid in Scotland: Families remember loved ones lost to coronavirus

We share the stories of some of the 12,000 people who have died with coronavirus in Scotland.

Stirlingshire
Stirling
United-kingdom
Crianlarich
Kilsyth
North-lanarkshire
Home-farm
Kwazulu-natal
South-africa
Clydebank
West-dunbartonshire
Ardrossan

Current Treatment Options in First-Line MCL

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Treatment-options
Cmcl
Btk-inhibitors
Indolent-biology
Intensive-therapy
Frontline-therapy
Consolidation-therapy
Fasct

Unmet Needs in Treating Relapsed/Refractory FL

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Bijal-shah
Laurie-sehn
Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Fl
Ctdna
Pod-24
Ezh2
Tumor-microenvironment
Immunotherapy

vimarsana © 2020. All Rights Reserved.